As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.
from NCI News Releases https://ift.tt/2MuIy5z
from NCI News Releases https://ift.tt/2MuIy5z